Pfizer expects to collect 100 billion USD in 2022

 Pfizer expects to collect 100 billion USD in 2022

Pfizer's revenue is forecast to grow strongly this year, with Covid-19 vaccines and drugs contributing more than half.

The US pharmaceutical company said that soaring sales of Covid-19 drugs and vaccines will continue to push the company's revenue in 2022 to $ 100 billion. In which, sales of antiviral drug Paxlovid will reach about 22 billion USD, and vaccine will reach 32 billion USD. Last year, Paxlovid brought in $76 million, while the vaccine was $36.8 billion.

Pfizer has made a number of recent acquisitions and partnerships to strengthen its ability to deliver drugs and vaccines. In December 2021, Pfizer said it would buy Arena Pharmaceuticals for $6.7 billion. The company has also invested $25 billion in business development since 2019.

Pfizer headquarters in New York, USA. Photo: Bloomberg

Pfizer headquarters in New York, USA. Photo: Bloomberg

With growing cash on hand, Pfizer said its acquisition strategy will focus on drugs that treat early- and late-stage diseases in areas where it is focused, such as oncology, immunity and rare diseases.

The New York-based drugmaker forecasts the new deals will generate $25 billion in additional revenue by 2030. "We want to deploy capital in areas where we have expertise to select the right targets. appropriate," said CEO Albert Bourla.

This could be the answer for analysts and investors, who are watching what Pfizer will do with the profits made from the pandemic. Revenue from vaccines and drugs to treat Covid-19 will gradually decrease over time. The company will also face reduced revenue due to products that have expired patent protection.

Shares of Pfizer fell more than 4% yesterday after the company released financial reports. The reason is that earnings forecasts are lower than investors' expectations, according to Evercore ISI analyst Umer Raffat.

CFO Frank D'Amelio said earnings per share (EPS) of $6.35 to $6.55 were already a record for them. In addition, Pfizer notes that this year's estimates include closed deals only. The company is still in discussions with more than 100 countries about the drug Paxlovid. So revenue could be $22 billion higher if they have more deals.